Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

Amanda Leach; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Kim Mulholland; Mathuram Santosham; Paul J. Torzillo; Peter McIntyre; Heidi Smith‐Vaughan; Sue Skull; Victor M. Oguoma; Mark D. Chatfield; Deborah Lehmann; Christopher G. Brennan‐Jones; Michael Binks; Paul V. Licciardi; Ross Andrews; Tom Snelling; Vicki Krause; Jonathan R. Carapetis; Anne B. Chang; Peter S Morris

doi:10.1371/journal.pmed.1004375

Abstract

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leach et al. (2024) studied this question.

synapsesocial.com/papers/68e66715b6db6435875f2c4d https://doi.org/10.1371/journal.pmed.1004375

View Full Paper

Ask AI

Bookmark

Share

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

Abstract

Discussion

Cite This Study

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

Abstract

Discussion

Cite This Study

Keep reading

Keep reading